

S6 Table. Patient characteristics of the matched cohort (chemotherapy alone vs. chemotherapy with ICI)

Characteristic	Chemotherapy alone (n=118)	Chemotherapy with ICI (n=59)	p-value	SMD
Age group (yr)			0.26	< 0.001
< 65	31 (26.3)	11 (18.6)		
≥ 65	87 (73.7)	48 (81.4)		
Sex			> 0.99	0.04
Female	12 (10.2)	6 (10.2)		
Male	106 (89.8)	53 (89.8)		
ECOG performance status			0.60	0.04
0-1	105 (89.0)	54 (91.5)		
2	13 (11.0)	5 (8.5)		
Smoking status			0.26	0.02
Never smoked	17 (14.4)	5 (8.5)		
Current or former smoker	101 (85.6)	54 (91.5)		
No. of involved extrathoracic sites			0.75	0.03
0-1	57 (48.3)	30 (50.8)		
≥ 2	61 (51.7)	29 (49.2)		
Brain metastasis at diagnosis			0.41	0.09
No	87 (73.7)	40 (67.8)		
Yes	31 (26.3)	19 (32.2)		
Bone metastasis at diagnosis			> 0.99	0.01
No	56 (47.5)	28 (47.5)		
Yes	62 (52.5)	31 (52.5)		
Liver metastasis at diagnosis			0.14	0.08
No	77 (65.3)	45 (76.3)		
Yes	41 (34.7)	14 (23.7)		
Pleural metastasis at diagnosis			0.53	0.07
No	93 (78.8)	44 (74.6)		
Yes	25 (21.2)	15 (25.4)		
Follow-up duration (mo)			0.23	0.11
< 10	49 (41.5)	19 (32.2)		
≥ 10	69 (58.5)	40 (67.8)		
Response to 1st line systemic therapy ^{a)}			0.18	0.02
SD or PD	16 (13.6)	4 (3.4)		
PR or CR	102 (86.4)	55 (46.6)		

CR, complete response; ECOG, Eastern Cooperative Oncology Group; ICI, immune check inhibitor; IQR, interquartile range; PD, progressive disease; PR, partial response; SD, stable disease; SMD, standardized mean difference; TRT, thoracic radiation therapy. ^{a)}Median number of 1st line systemic therapy cycles was 6 (IQR, 4 to 6) in the chemotherapy alone group; 4 (IQR, 4 to 4) in the ICI group.